ShareValue scores for TMDX: Valuation 56, Quality 73, Growth 69, Health 52.

TransMedics Group Inc logo

TMDX
NASDAQ

TransMedics Group Inc

$89.36(+1.07%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

8% to 17%
Valuation
56
Fair Value
Price vs Value
Quality
73
Strong
Business Strength
Growth
69
Moderate
Revenue & Earnings
Health
52
Moderate
Financial Stability
Momentum
4
Bearish
Price Trend

Company Details

About

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Score Analysis

AI Investment Thesis

Data as of:Aug 12, 2026
|
Last calculated:Aug 12, 2026